MARY ARMITAGE: Open Payments
NPI 1891150314 · FULSHEAR, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,361 in 74 payments from 14 companies in 2025. Trend: 2023 $1,075 · 2024 $1,249 · 2025 $1,361
Food & beverage: $1,352Education: $10
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $430 |
| Novo Nordisk Inc | 13 | $223 |
| AstraZeneca Pharmaceuticals LP | 5 | $194 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $88 |
| Lilly USA, LLC | 4 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| Exact Sciences Corporation | 4 | $69 |
| PFIZER INC. | 3 | $56 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $25 |
Products named: QULIPTA, FARXIGA, Ozempic, VRAYLAR, UBRELVY, Kerendia, REXULTI, Wegovy.
Industry payments across TX — which companies pay providers there.
